RecruitingPhase 3NCT07520565

A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.

Studying Androgen insensitivity syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Biocells (Beijing) Biotech Co.,Ltd
Intervention
BXOS110(drug)
Enrollment
1112 target
Eligibility
18-85 years · All sexes
Timeline
20262027

Study locations (9)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07520565 on ClinicalTrials.gov

Other trials for Androgen insensitivity syndrome

Additional recruiting or active studies for the same condition.

See all trials for Androgen insensitivity syndrome

← Back to all trials